Skip to main content
. 2019 Oct 31;38(3):644–654. doi: 10.1016/j.vaccine.2019.10.049

Table 1.

Study Design Information.

Study ID Study Group Assignment Vaccination Day MPXV Challenge Day MPXV Target Challenge Dose (PFU, IV)
Study 1 Controls 0 45 5.0E + 07
ACAM2000 + Placebo
ACAM2000 + Tecovirimat



Study 2 ACAM2000 + Placebo 0 30 5.0E + 07
ACAM2000 + Tecovirimat



Study 3 ACAM2000 + Placebo 0 32 5.0E + 07
ACAM2000 + Tecovirimat